CagriSema
cagrilintide semaglutide · REDEFINE trial · amylin GLP-1 combo
Novo co-formulation: cagrilintide 2.4 mg plus semaglutide 2.4 mg in the trials. Mixing two cakes is not REDEFINE. Not scored as an approved US obesity pen on this catalog date.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight8/10
Phase 3 REDEFINE / CagriSema program. Ceiling 8 until a US finished-product label. Do not score a home mix of two cakes as the co-formulation.
Compound card
- Sequence
- Cagrilintide 2.4 mg + semaglutide 2.4 mg (fixed-ratio)
- Class
- Once-weekly amylin + GLP-1 co-formulation (Novo; not a DIY mix)
- Formula
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg (co-formulation)
- Status
- Cagrilintide + Semaglutide combination; REDEFINE Phase 3 ongoing
How it works
CagriSema is a fixed-ratio co-formulation combining cagrilintide 2.4 mg (long-acting amylin analog) and semaglutide 2.4 mg (GLP-1 receptor agonist) in a single weekly subcutaneous injection. The rationale is mechanistic complementarity - amylin and GLP-1 receptors are anatomically distinct and act via independent neuronal pathways in the hypothalamus and brainstem satiety circuits.
GLP-1 agonism reduces appetite primarily via hypothalamic and vagal pathways. Amylin agonism acts via area postrema and nucleus tractus solitarius with additive appetite suppression and greater gastric emptying inhibition. In PHASE III, CagriSema achieved 22.7% mean weight loss at 68 weeks - exceeding any approved monotherapy GLP-1 agonist at the time.
Source: PMID: 35948058 (CAGRISEMA Phase 2), NCT05634603 (REDEFINE Phase 3)
Goal context
Two hormones, one protocol
GLP-1 and amylin sit on different receptors. That is the point of the combo and the reason a kitchen stack is not the trial.
Background & History
CagriSema is Novo’s co-formulation: cagrilintide plus semaglutide in the trials. Mixing two cakes is not REDEFINE. Not scored as an approved US obesity pen on this catalog date.
Research Use Cases
- ✓Fixed-ratio identity vs DIY dual-vial math
- ✓Why REDEFINE percents do not transfer to compounded fills
- ✓Not a metabolic-syndrome treatment page
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Phase III Protocol | 2.4 mg cagrilintide + 2.4 mg semaglutide | Once weekly SC injection | Fixed-ratio co-formulation. Not yet FDA-approved. Phase III data published 2024. |
Administration
Timeline
Who it is for
Obesity / Weight Loss
EmergingPhase III shows 22.7% weight loss - superior to any approved GLP-1 monotherapy. Pending FDA approval.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| Trial / branded co-formulation | n/a (device when labeled) | Fixed 2.4 + 2.4 | Do not recon a pen. Do not treat two cakes as this product. |
Change vial size or water volume? Open the blend calculator.
Safety & Considerations
Investigational drug (not FDA-approved as of 2024). Phase III safety profile similar to component monotherapies. Being evaluated for cardiovascular outcomes. Expect approval in 2025-2026.
Regulatory & Legal Status
Cagrilintide + Semaglutide combination; REDEFINE Phase 3 ongoing
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Investigational
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Trial percents describe the co-formulation, not two research vials drawn into one syringe.
- Not scored as an approved US obesity pen on this leaf’s date.
- GI dropout and lean-mass loss still apply. Dual pathway is not “no side effects.”
Verdict
CagriSema is Novo’s co-formulation, two receptors, one pen in the trials. Mixing a cagrilintide cake with a semaglutide cake is not REDEFINE. Do not stack a third incretin on top.
Interactions & Contraindications
Dual GI mechanism. MTC/MEN2 class. Investigational as a branded combo. Compounded copies are not the trial pen.
Synergies & Common Stacks
Already in the product. Do not add a third incretin.
Frequently Asked Questions
What weight loss does CagriSema produce?▼
When will CagriSema be FDA-approved?▼
References
- Lau DCW et al. “"CagriSema Phase III (REDEFINE 1): 22.7% weight loss at 68 weeks".” Lancet (2024). PMID: 38733994
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code